NTD Treatment Market
Global NTD Treatment Market Size, Share & Trends Analysis Report By disease (Dengue, Rabies, Trachoma, Buruli ulcer, leprosy, Chagas disease, and Others), By Treatment (Drugs and Vaccines), By End-Use (Government & Individual) Forecast Period 2020-2026
The NTD treatment market is anticipated to grow at a more than CAGR of 8% during the forecast period. NTDs are a diverse group of parasitic and bacterial diseases that cause prevail in tropical and subtropical conditions. Some of the NTD is communicable in nature also. According to the World Health Organization (WHO), NTDs prevalence is in approximately 149 countries affecting more than one billion people across the globe.
Raising awareness regarding various NTD in emerging economies, increasing individual disposable income, development of new drugs and vaccines are driving the NTD treatment market during the forecast period. Moreover, the implementation of various appropriate measures and policies by the government and global health organizations for NTD elimination is contributing significantly to the NTD treatment market. For instance, WHO’s NTD Roadmap is an initiative working on NTD for the elimination and the eradication of at least two NTD by 2020. However, the underdeveloped health care sector is presenting restraint to the growth of the NTD treatment market in the emerging economies during the forecast period.
Segmental Outlook
The global NTD treatment market is segmented based on disease and treatment. Based on the disease, the market is sub-segmented into dengue, rabies, trachoma, Buruli ulcer, leprosy, Chagas disease, and others. Further, based on the treatment, the market is bifurcated into drugs and vaccines. On the basis of end-user, the market is bifurcated into public and individual.
The dengue segment by the disease will show considerable growth
The dengue segment is anticipated to hold a significant market share in the NTD treatment market. Dengue fever is considered to be one of the fastest-growing infectious diseases across the globe. According to the WHO estimates, there are around 390 million cases of dengue each year, with as many as two and a half billion people at risk from the disease. Hence, the high prevalence of NTD treatment is expected to significantly contribute to the NTD treatment market.
Global NTD treatment market Share by disease, 2019 (%)
Regional Outlooks
The global NTD treatment market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is anticipated to hold the major market share with a significant growth rate owing to the raising initiatives to eliminate NTD across the countries. For instance, since 2013, the Organisation of Pharmaceutical Producers of India (OPPI) in collaboration with Global Health Progress (GHP) and International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) are working on the elimination of NTD in India. Moreover, the presence of a huge target population in Asian countries will also contribute to the growth of the NTD treatment market.
Besides, the Rest of the world that consists of Latin America and the Middle East & African countries is expected also expected to showcase a significant growth rate in the NTD treatment market. The burden of NTD diseases is increasing significantly across these countries. Additionally, raising awareness of NTD treatment coupled with the surge in various initiatives by global health organizations in the region will also aid in the growth of the NTD treatment Market.
Global NTD Treatment Market Growth, by Region 2020-2026
Market Players Outlook
The key players of the NTD treatment market include Abbvie Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Humanigen, Inc., Merck KGaA, Takeda Pharmaceutical Co. Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger, and acquisition, collaborations with government, funding to the start-ups, and new product launches to stay competitive in the market.
Recent Activity
- In June 2018, Pfizer Inc. extended its donation of the trachoma preventive drug Zithromax (azithromycin) to all those at risk to 2025.
- In April 2018, Takeda Pharmaceutical Co. Ltd. collaborated with Drugs for Neglected Diseases initiative (DNDi) to progress the development of a potential new drug for Visceral Leishmaniasis. Through the collaboration, the company is conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the amino pyrazole compound class, aimed for the treatment of visceral leishmaniasis.
- In August 2017, InsudPharma S.L.U. received FDA approval for its benznidazole drug that is intended for the treatment of Chagas Disease in children.
- In April 2017, Merck KGaA donated $300,000 in cash to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF) in Africa.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global NTD treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Business Functions and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AbbVie Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Eisai Co., Ltd.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. F. Hoffmann-La Roche Ltd.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Humanigen, Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Merck KGaA
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global NTD Treatment Market by Disease
5.1.1. Dengue
5.1.2. Rabies
5.1.3. Trachoma
5.1.4. Buruli ulcer
5.1.5. Leprosy
5.1.6. Chagas disease
5.1.7. Others
5.2. Global NTD Treatment Market by Treatment
5.2.1. Drugs
5.2.2. Vaccines
5.3. Global NTD Treatment Market by End-User
5.3.1. Government/ Public
5.3.2. Individual
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. Western Europe
6.2.2. Eastern Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. ASEAN
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East
6.4.3. Africa
7. Company Profiles
7.1. Abbott Laboratories
7.2. AbbVie Inc.
7.3. Astellas Pharma Inc.
7.4. Bayer AG
7.5. CadilaHealthcare Ltd.
7.6. Daiichi Sankyo Company, Ltd.
7.7. Eisai Co., Ltd.
7.8. Eli Lilly & Co.
7.9. F. Hoffmann-La Roche Ltd.
7.10. Gilead Sciences, Inc.
7.11. GlaxoSmithKline plc
7.12. Humanigen, Inc.
7.13. Insud Pharma S.L.U.
7.14. Merck KGaA
7.15. Novartis AG
7.16. Oblita Therapeutics
7.17. Pfizer Inc.
7.18. Sanofi SA
7.19. Sun Pharmaceutical Industries Ltd.
7.20. Takeda Pharmaceutical Company Ltd.
7.21. Teva Pharmaceutical Industries Ltd.
1. GLOBAL NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
2. GLOBAL DENGUE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL RABIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL TRACHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL BURULI ULCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
6. GLOBAL LEPROSY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
7. GLOBAL CHAGAS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
8. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
9. GLOBAL NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
10. GLOBAL DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
11. GLOBAL VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
12. GLOBAL NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
13. NORTH AMERICA NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
14. NORTH AMERICAN NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
15. NORTH AMERICAN NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
16. NORTH AMERICAN NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
17. EUROPE NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
18. EUROPE NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
19. EUROPE NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
20. EUROPE NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
21. ASIA-PACIFIC NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
22. ASIA-PACIFIC NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
23. ASIA-PACIFIC NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
24. ASIA PACIFIC NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
25. REST OF THE WORLD NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
26. REST OF THE WORLD NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
27. REST OF THE WORLD NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
28. REST OF THE WORLD NTD TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2019-2026 ($ MILLION)
1. GLOBAL NTD TREATMENT MARKET SHARE BY DISEASE, 2019 VS 2026 (%)
2. GLOBAL NTD TREATMENT MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
3. GLOBAL NTD TREATMENT MARKET SHARE BY END-USER, 2019 VS 2026 (%)
4. GLOBAL NTD TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
5. US NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
6. CANADA NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
7. WESTERN EUROPE NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
8. EASTERN EUROPE NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
9. CHINA NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
10. INDIA NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
11. ASEAN NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
12. REST OF ASIA-PACIFIC NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
13. LATIN AMERICA NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
14. MIDDLE EAST NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
15. AFRICA NTD TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
